Eikon Therapeutics Inc., a late-stage cancer drug developer led by Merck & Co. veterans, raised $381.2 million in an upsized US initial public offering.
The Millbrae, California-based firm sold 21.18 million shares at $18 each, according to a statement Wednesday. The company had marketed 17.65 million shares for $16 to $18. Prior to the upsize, Merck was expected to buy about 10% of shares in the offering, people familiar with the matter have said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.